SynthesisAmerican journal of hematology2025

Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.

Ioannis Ntanasis-Stathopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.